TCLIF Theraclion SA (PNK) $0.53 on 09 Apr 2026: top gainer, volatile

TCLIF stock opened the regular session at $0.53 on 09 Apr 2026 after a sharp move from a prior close of $0.00 (reported previous close $0.00 / data shows jump from $0.00017). The small-cap healthcare name, Theraclion SA (TCLIF) on the PNK exchange in the United States (USD), recorded a market cap of $25,090,822.00 and volume 500 shares. This article breaks down the price drivers, financial ratios, technical setup and Meyka AI forecast as the stock sits among today’s top gainers during market hours.

TCLIF stock movement and intraday facts

TCLIF stock is trading at $0.53 with a day low and high both at $0.53, reflecting a highly concentrated print and low liquidity. The reported volume is 500 versus an average volume of 51, producing a relative volume near 1.96. Market cap stands at $25,090,822.00 with 47,163,200 shares outstanding and an EPS of -273.92, signaling extreme earnings volatility.

Drivers behind the top gainer status for TCLIF stock

The immediate price move appears tied to low float dynamics, thin trading and renewed investor attention to Theraclion’s echotherapy product line. Key catalysts include an upcoming earnings announcement on 2026-04-27 and any regulatory or sales updates for SONOVEIN and ECHOPULSE. Sector context: Healthcare medical devices are mixed, so company-specific news is the likely driver rather than broad sector flows.

Meyka AI rates TCLIF with a score out of 100 and forecast

Meyka AI rates TCLIF with a score out of 100: 65.66 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year price of $0.02, which implies an estimated downside of -95.91% versus the current $0.53. Forecasts are model-based projections and not guarantees.

TCLIF stock valuation and financial metrics

On trailing metrics Theraclion shows strained fundamentals: EPS -273.92, price-to-sales 0.00 (rounded 0.00), book value per share near zero and a negative PB ratio around -59.26. Current ratio is 2.21 and cash per share is $0.09, indicating short-term liquidity but weak profitability. Revenue per share TTM is $0.04, and free cash flow per share TTM is -0.03.

Technicals, trading signals and volatility for TCLIF stock

Technicals show extreme readings: RSI 100.00 (overbought), ROC 312,841.18%, ADX 98.41 (strong trend). Bollinger Band middle $0.03 and upper $0.26 reflect recent compression prior to the move. Average true range is 0.10, but with low volume the risk of sharp reversals is high. Traders should expect heightened intraday swings.

Risks, catalysts and scenario-based price targets for TCLIF stock

Principal risks include low liquidity, accounting of the prior tiny close ($0.00017), no active analyst coverage, and negative profitability metrics. Catalysts to watch: the 2026-04-27 earnings release and any regulatory or reimbursement news for echotherapy devices. Scenario targets: conservative $0.02 (Meyka model), base $0.50 (stabilization), bullish $1.00 (positive commercial or regulatory surprise).

Final Thoughts

TCLIF stock traded at $0.53 on 09 Apr 2026 as a top gainer in a low-liquidity session. Our review highlights extreme technical readings (RSI 100.00), fragile fundamentals (EPS -273.92) and concentrated volume (500 shares). Meyka AI’s forecast model projects $0.02 in one year, implying an estimated downside of -95.91% versus today’s price; forecasts are model-based projections and not guarantees. Meyka AI rates TCLIF with a score out of 100 at 65.66 (Grade B, HOLD), reflecting mixed signals: potential for event-driven upside but high execution and liquidity risk. Short-term traders may find volatility, while longer-term investors should await clearer revenue or regulatory proof points before increasing exposure. We present price scenarios from $0.02 to $1.00 to frame risk and reward and recommend monitoring the 2026-04-27 earnings and device approval updates before taking positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.